Log in to MyACC
New York Cardiovascular Symposium
December 8 − 10, 2017
New York Hilton Midtown
New York City
Course Director(s): Valentin Fuster, MD, PhD, MACC
Conflict of Interest (COI) Policy / Disclosures
ACCF committee members, faculty, staff and other individuals who are in a position to control the content of this activity are required to disclose all relevant financial relationships he/she and/or his/her spouse or domestic partner has, occurring within the past twelve months, with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. All relevant potential conflicts of interest that are identified are thoroughly vetted through a process that includes course directors and appropriate peer review by education committee chairs/members, for fair balance, scientific objectivity and validity, patient care and safety recommendations. Refer to the links below for committee member disclosures and course faculty disclosures. Please note ACCF staff involved with this course have nothing to disclose.
|
Friday, December 8 |
||
|
Coronary Artery Disease -- Challenges in 2017 |
||
| 7:30 a.m. |
Vascular 3D-Ultrasound in Subclinical Systemic Disease: 12,000 Subjects Feasible, Predictable, Preventable, Futurable Dr. Fuster |
|
| 8:00 a.m. |
Intravascular Optical Coherence Tomography in Clinical CAD: 1,400 Patients Feasibility, Predictability, Preventability, Futurability Dr. Jang |
|
| 8:25 a.m. |
Genomics in Myocardial and Structural Heart Disease From Generic to a Personalized Cardiovascular Approach Dr. Seidman |
|
| 8:50 a.m. |
Panel Discussion Drs. Fuster, Jang, and Seidman |
|
|
Session II: Acute Coronary Syndromes (ACS) |
||
| 9:40 a.m. |
STEMI 1: Timing, Mechanical Type and Pharmacology of Reperfusion The Three Main Challenges to Decrease Infarct Size and Increase Viability Dr. Ibáñez |
|
| 10:05 a.m. |
SSTEMI 2: PCI of Culprit Lesion Alone vs. FFR Guided Complete Revascularization Effects on Hard End Points, MACE and Cost Effectiveness Dr. Bhatt |
|
| 10:30 a.m. |
STEMI vs. NSTEMI vs. STABLE CAD – Post PCI Optimal DAPT Duration Scoring the Complexity of Stenting and Disease Dr. Yeh |
|
| 10:55 a.m. |
STEMI vs. NSTEMI vs. STABLE CAD – Five Challenging Cases Five Challenging Antithrombotic Approaches Dr. Levine |
|
| 11:25 a.m. |
Panel Discussion Drs. Bhatt, Ibáñez, Levine and Yeh |
|
|
Session III: Systemic Arterial Disease -- Chronic Coronary Disease, Stroke and Pulmonary Embolism |
||
| 1:00 p.m. |
Chest Pain Evaluation: Possible vs. Probable CAD No Test, Stress Test or CT Angio? Dr. Douglas |
|
| 1:20 p.m. |
Complex Stable CAD: Evolving Evaluation and Management Strategies Evaluate: Anatomy (SYNTAX), Ischemia (IFR), Microcirculation (CT, MRI) Manage: Optimal Medical Therapy (OMT), PCI (Stents), CABG (IMA) Dr. Fuster |
|
| 1:45 p.m. |
Acute Ischemic Stroke and Chronic Carotid Artery Stenosis Two Entities with Novel Approaches Dr. Brott |
|
| 2:05 p.m. |
Pulmonary Emboli: Diagnosis Based on Suspicion and Management in 2017 Based on the Acute Severity and Degree of Chronic PH Dr. Piazza |
|
| 2:25 p.m. |
Panel Discussion Drs. Brott, Douglas, Fuster and Piazza |
|
|
Session IV: Trends and Challenges of Approaching Prevention |
||
| 3:15 p.m. |
Aspirin in Primary and Secondary Cardiovascular Disease Prevention: Still Four Questions About Enteric Coated, Indicated Doses, Use in Diabetes, Use in PVD Dr. Patrono |
|
| 3:35 p.m. |
Lipid Evaluation and Management: Four Evolving “Advances” Familial LDL-C, ApoB, HDL Efflux Capacity and PCSK9 Inhibitors Dr. Rader |
|
| 4:00 p.m. |
Hypertension (HBP) Evaluation and Management: Three Challenges Identify Those with HBP, Reduce Salt (Amount?) and Personalize BP Target Dr. Spatz |
|
| 4:25 p.m. |
Diabetes and Obesity: The Four “Hot Spots” Mechanisms of Diabetes, New Agents for Macrovascular Diabetes Weight vs. Obesity in AF, Bariatric Surgery Dr. Fuster |
|
| 4:50 p.m. |
Panel Discussion Drs. Fuster, Patrono, Rader and Spatz |
|
| 5:30 p.m. | Adjournment | |
|
Saturday, December 9 |
||
|
Cardio-pulmonary and Electrical Failure 2017 |
||
| 7:00 a.m. |
Imaging (Echo, MRI, PET) as Diagnostic and Prognostic Tools For Seven Cardiomyopathies: Myocarditis, Dilated CM, Hypertrophic CM, Noncompaction LV, Amyloid CM, Sarcoid and Takotsubo Dr. Bonow |
|
| 7:25 a.m. |
Therapeutic Approaches to Three Specific Cardiomyopathies Acute/Subacute Myocarditis, AL/TTR Amyloid, Non-compaction LV Dr. Dec |
|
| 7:50 a.m. |
Systolic and Diastolic Dysfunction: Three Upcoming Challenges Promoting Early Detection HFrEF: Beyond Neprilysin/Enalapril HFmrEF: What Is It and How Does One Manage It? HFpEF: Etiopathogenetic Role and Impact of Comorbidities Dr. Mann |
|
| 8:20 a.m. |
Advanced Heart Failure ΜΆ The Three Upcoming Challenges Acute Heart Failure: Is It a Disease that Can Be Treated? Comorbidities in Heart Failure: Emerging Positive Signals End Stage Heart Failure: Are We Doing Better? Dr. O’Connor |
|
| 8:45 a.m. |
State-of-the-Art Management of Pulmonary Hypertension Monitoring and Approach of the Three Main Etiopathogenesis L-Sided Failure, Pulmonary Arterial Hypertension, Thromboembolic Dr. Gomberg-Maitland |
|
| 9:10 a.m. |
Panel Discussion Drs. Bonow, Dec, Gomberg-Maitland, Mann and O'Connor |
|
|
Session VI: Rhythm Disorders, Contemporary and Future Topics of Focus |
||
| 10:00 a.m. |
Innovations in Device Therapies: Three Approaches CRTs, the Right Indications, Subcutaneous ICDs, Leadless Pacemakers Dr. Wilber |
|
| 10:25 a.m. |
Ventricular Tachycardia: Catheter Ablation – Four Questions Who? When? How? Results? Dr. Reddy |
|
| 10:50 a.m. |
Atrial Fibrillation: Catheter Ablation – Four Questions Who? When? How? Results? Dr. Marchlinski |
|
| 11:15 a.m. |
Left Atrial Appendage Closure: Four Questions Who? When? How? Results? Dr. Holmes |
|
| 11:40 a.m. |
Atrial Fibrillation 2017: The Fourteen Non-ablation Clinical Challenges Quality of Life and Preventing Stroke Dr. Fuster |
|
| 12:00 p.m. |
Panel Discussion Drs. Fuster, Holmes, Marchlinski, Reddy and Wilber |
|
|
Valvular Heart Disease and Aorta – Challenges in 2017 |
||
| 1:30 p.m. |
Aortic Valvular Stenosis: How to Assess the Four Variables for Management Low Flow / Low Gradient / Normal EF / Low EF Dr. O'Gara |
|
| 1:50 p.m. |
Severe Aortic Valvular Disease: TAVR in Four Ages and Four Etiologies Age 25 y/o Congenital, 50 y/o Bicuspid, 75 y/o Rheumatic, 100 y/o Degenerative Drs. Adams, Nishimura and Sharma |
|
| 2:20 p.m. |
The Dilated Thoracic and Abdominal Aorta and Complicating Dissection Evolving Understanding of the Basic Biology and Management Dr. Fuster |
|
| 2:45 p.m. |
Panel Discussion Drs. Adams, Fuster, O'Gara, Nishimura and Sharma |
|
|
Session VIII: Management of Mitral Regurgitation and Hypertrophic Cardiomyopathy |
||
| 3:35 p.m. |
Significant Mitral Regurgitation (EF, LVEdD, PH or AF): Five Challenges Two Etiologies (Primary, Secondary), Three Approaches (Medical, Clipping, Surgical) Drs. Adams, Bonow and Sharma |
|
| 4:05 p.m. |
Transcatheter Replacement for Mitral and Tricuspid Regurgitation Evolving Approaches Under Investigation Dr. Rodés-Cabau |
|
| 4:30 p.m. | Hypertrophic Cardiomyopathy: Four Challenging Questions Genetics/Acquired, Myectomy/Three Types, Natural Hx/ICD, Apical Aneurysm Dr. Nishimura |
|
| 4:55 p.m. |
Panel Discussion Drs. Adams, Bonow, Nishimura, Rodés-Cabau and Sharma |
|
| 5:30 p.m. | Adjournment | |
|
Sunday, December 10 |
||
|
Year in Review: The Nine Highlights of Progress in Dr. Fuster, Presiding |
||
| 7:30 a.m. |
Part 1: Progress in Genetic Medicine – Genome Editing A New Understanding of Cardiovascular Physiology, Pathology and Future Therapies Dr. Musumuru |
|
| 7:55 a.m. |
Part 2: Progress in Molecular Cardiovascular Medicine – MicroRNAs, Proteomics and Metabolomics A New Understanding of Cardiovascular Physiology, Pathology and Future Therapies Dr. Mayr |
|
| 8:20 a.m. |
Part 3: Progress in Myocardial Regeneration – Exosomes and iPCs A New Understanding of Cardiovascular Physiology, Pathology and Future Therapies Dr. Janssens |
|
|
Session X: Novelties on Diagnostic and Therapeutic Strategies |
||
| 8:45 a.m. |
Part 1: Evolving Progress of Cardiovascular Imaging Redefining Its Role in Biomedical Research and Clinical Practice Dr. Di Carli |
|
| 9:10 a.m. |
Part 2: Evolving Progress of Coronary Interventional Stents Bioresorbable Scaffolds – Moving Forward or Backwards? Dr. Dangas |
|
| 9:35 a.m. |
HENRY RUSSEK LECTURE 2017 Part 3: The Known and Unknown of Transcatheter Aortic Valve Thrombosis Dr. Bax |
|
|
Session XI: Aiming at the Future of Medicine |
||
| 10:20 a.m. |
Part 1: The Future of Promoting Health Should Children’s Education Be the Priority Focus? Dr. Fuster |
|
| 10:45 a.m. | Part 2: Evolving Progress of Atherothrombotic Therapies Reducing Inflammation to Reduce Cardiovascular Risk: The CANTOS Trial Dr. Ridker |
|
| 11:15 a.m. |
PAUL DUDLEY WHITE LECTURE 2017 Part 3: The Future of Personalized Cardiovascular Medicine A Practical Reality or a Dream Not Economical Feasible? Dr. Califf |
|
| 11:45 a.m. | Course Adjournment | |
